Gene therapy approaches for the selective killing of cancer cells.

abstract：BACKGROUND:Pulmonary diseases are the third leading cause of morbidity worldwide, however treatment and diagnosis of these diseases continue to be challenging due to the complex anatomical structure as well as physiological processes in the lungs. METHODS:3D printing is progressively finding new avenues in the medical...

journal_title：Current pharmaceutical design

authors： Haque S,Md S,Whittaker M,Kaminskas LM

更新日期：2018-01-01 00:00:00

abstract：:The mechanisms underlying neurodegeneration in amyotrophic lateral sclerosis (ALS) are multifactorial and include genetic and environmental factors. Nowadays, it is well accepted that neuronal loss is driven by non-cell autonomous toxicity. Non-neuronal cells, such as astrocytes, have been described to significantly c...

journal_title：Current pharmaceutical design

authors： Johann S

更新日期：2017-01-01 00:00:00

abstract：:Hereditary hemorrhagic telangiectasia (HHT) is characterized by vessel alterations such as dilatation of postcapillary venules and arterio-venous communications, which account for the major clinical manifestations of the disease. Two types of HHT have been characterized HHT-1 and HHT-2, respectively, depending the for...

journal_title：Current pharmaceutical design

authors： Jirillo E,Amati L,Suppressa P,Cirimele D,Guastamacchia E,Covelli V,Tafaro E,Sabbà C

更新日期：2006-01-01 00:00:00

abstract：:Alzheimer's disease (AD) is a progressive age-related neurodegenerative disorder with distinct neuropathological features. Extracellular plaques, consisting of aggregated amyloid peptides of 39-43 amino acids are one of the most prominent pathological hallmarks of this disease. Although the exact neurochemical effecto...

journal_title：Current pharmaceutical design

authors： Hajieva P,Behl C

更新日期：2006-01-01 00:00:00

abstract：:The increasing prevalence of persistent biofilm infections, such as wound infections, chronic lung infections or medical device- related infections, which usually tolerate conventional antibiotic treatment, calls for the development of new therapeutic strategies. To date, antimicrobial peptides (AMPs) are considered a...

journal_title：Current pharmaceutical design

authors： Strempel N,Strehmel J,Overhage J

更新日期：2015-01-01 00:00:00

abstract：:Inhibition of carbonic anhydrase (CA, EC 4.2.1.1) isoforms present in the eyes (CA I, II, IV and XII), with sulfonamides such as acetazolamide, methazolamide, ethoxzolamide and dichlorophenamide, is still widely used for the systemic treatment of glaucoma. The mechanism of action of these drugs consists in inhibition ...

journal_title：Current pharmaceutical design

authors： Mincione F,Scozzafava A,Supuran CT

更新日期：2008-01-01 00:00:00

abstract：:Diabetic patients are considered as high risk for development of atherosclerotic disease. Cholesterol treatment is of paramount importance in order to optimise cardiovascular outcomes in this subset of patients. Although statins are regarded as the mainstay of treatment, these may not be tolerated or as efficacious as...

journal_title：Current pharmaceutical design

authors： Felekos I,Karamasis GV,Pavlidis AN

更新日期：2020-06-17 00:00:00

abstract：:Angiogenesis, the development of new capillaries form pre-existing vessels, requires the coordinate activation of endothelial cells, which migrate and proliferate in response to growth factors to form functional vessels. Therapeutic angiogenesis is proposed to restore tissue integrity and function following damage and...

journal_title：Current pharmaceutical design

authors： Morbidelli L,Donnini S,Ziche M

更新日期：2003-01-01 00:00:00

abstract：:Protein-protein interactions (PPI) are involved in vital cellular processes and are therefore associated to a growing number of diseases. But working with them as therapeutic targets comes with some major hurdles that require substantial mutations from our way to design drugs on historical targets such as enzymes and ...

journal_title：Current pharmaceutical design

authors： Villoutreix BO,Labbé CM,Lagorce D,Laconde G,Sperandio O

更新日期：2012-01-01 00:00:00

abstract：:In 2007, the American Heart Association (AHA) recommended (class IIa, level of evidence B) in their guidelines on Perioperative Cardiovascular Evaluation and Care for Noncardiac Surgery volatile anesthetics as first choice for general anesthesia in hemodynamically stable patients at risk for myocardial ischemia. This ...

journal_title：Current pharmaceutical design

authors： Zaugg M,Lucchinetti E,Behmanesh S,Clanachan AS

更新日期：2014-01-01 00:00:00

abstract：:The beneficial effect of antihypertensive treatment on the risk of major vascular events is well established. Several trials comparing older and newer drugs in the treatment of primary hypertension suggested that it is the blood pressure achieved, rather than choice of the drug that determines most of the primary outc...

journal_title：Current pharmaceutical design

authors： Karagiannis A,Mikhailidis DP,Kakafika AI,Tziomalos K,Athyros VG

更新日期：2007-01-01 00:00:00

abstract：:Adenosine is released in large amounts during myocardial ischemia and is capable of exerting potent cardioprotective effects in the heart. Although these observations on adenosine have been known for a long time, how adenosine acts to achieve its anti-ischemic effect remains incompletely understood. However, recent ad...

journal_title：Current pharmaceutical design

authors： Liang BT,Jacobson KA

更新日期：1999-12-01 00:00:00

abstract：:Phytoestrogens are plant-derived compounds with estrogen-like activities. Certain foods such as soy-derived products are known to have high levels of phytoestrogens, and about 25% of commercial infant formulas used in the United States are soy-based. One of the most important phytoestrogens is the isoflavone genistein...

journal_title：Current pharmaceutical design

authors： You L

更新日期：2004-01-01 00:00:00

abstract：:Inhaled glucocorticoids, also know as corticosteroids (ICS), revolutionized the treatment of asthma by suppressing airways inflammation and ICS therapy now forms the basis of treatment of asthma of all severities. More recently and usually in combination with a long-acting β-agonist (LABA), ICS use has been establishe...

journal_title：Current pharmaceutical design

authors： Adcock IM,Marwick J,Casolari P,Contoli M,Chung KF,Kirkham P,Papi A,Caramori G

更新日期：2010-01-01 00:00:00

abstract：:Cardiovascular disease (CVD) is one of the major lifestyle associated disorders and leading causes of death worldwide. The incidence of CVD in diabetic patients has increased up to 3 folds and it became the major risk for diabetes associated morbidity and mortality. Insulin resistance and oxidative stress both play a ...

journal_title：Current pharmaceutical design

authors： Bagul PK,Banerjee SK

更新日期：2013-01-01 00:00:00

abstract：:A wide range of peptides and polypeptides can be appended to either the N- or C-terminus of G protein-coupled receptors without disrupting substantially ligand binding and signal transduction. Following fusion of fluorescent proteins, reporter gene constructs or G protein alpha subunits to the C-terminal tail of a rec...

journal_title：Current pharmaceutical design

authors： Milligan G,Feng GJ,Ward RJ,Sartania N,Ramsay D,McLean AJ,Carrillo JJ

更新日期：2004-01-01 00:00:00

abstract：:Protein stability of hypoxia-inducible factor (HIF)alpha subunits is regulated by the oxygen-sensing prolyl-4-hydroxylase domain (PHD) enzymes. Under oxygen-limited conditions, HIFalpha subunits are stabilized and form active HIF transcription factors that induce a large number of genes involved in adaptation to hypox...

journal_title：Current pharmaceutical design

authors： Wenger RH,Camenisch G,Stiehl DP,Katschinski DM

更新日期：2009-01-01 00:00:00

abstract：:The octapeptide angiotensin II (Ang II) plays a homeostatic role in the regulation of blood pressure and water and electrolyte balance, and also contributes to the progression of cardiovascular remodeling. Ang II activates Ang II type 1 (AT1) receptor and type 2 (AT2) receptor, both of which belong to the seven-transm...

journal_title：Current pharmaceutical design

authors： Akazawa H,Yano M,Yabumoto C,Kudo-Sakamoto Y,Komuro I

更新日期：2013-01-01 00:00:00

abstract：:Effective blood pressure control with a large arsenal of conventional antihypertensive drugs, such as diuretics, beta-adrenergic blockers, and calcium channel blockers, significantly reduce the morbidity and mortality associated with cardiovascular disease. However, blood pressure control with these drugs does not red...

journal_title：Current pharmaceutical design

authors： Igic R,Behnia R

更新日期：2007-01-01 00:00:00

abstract：BACKGROUND:Atherosclerosis is a chronic inflammatory disease and a leading cause of coronary artery disease, peripheral vascular disease and stroke. Lipid-laden macrophages are derived from circulating monocytes and form fatty streaks as the first step of atherogenesis. METHODS:An electronic search in major databases ...

journal_title：Current pharmaceutical design

authors： Taghizadeh E,Taheri F,Renani PG,Reiner Ž,Navashenaq JG,Sahebkar A

更新日期：2019-01-01 00:00:00

abstract：:Guidelines for the treatment of hypertension allow a wide range of choices to the physicians; however some differences are present about the preferred drugs to start treatment. The most important aim remains an adequate decrease of blood pressure, something not perfectly obtained in the general population, but some cl...

journal_title：Current pharmaceutical design

authors： Pende A,Dallegri F

更新日期：2012-01-01 00:00:00

abstract：BACKGROUND:Dietary supplements have been widely used among the United States of America (USA) and the European Union (EU) population not only as a form of nutrition but also for medicinal purposes. Still, the legislation regulating these supplements remains unclear due to the fact that they can be considered as foodstu...

journal_title：Current pharmaceutical design

authors： Pereira C,Barros L,Ferreira ICFR

更新日期：2017-01-01 00:00:00

abstract：:Pulmonary surfactant, a complex of lipids and proteins, functions to keep alveoli from collapsing at expiration. Surfactant proteins A (SP-A) and D (SP-D) belong to the collectin family and play pivotal roles in the innate immunity of the lung. Pulmonary collectins directly bind with broad specificities to a variety o...

journal_title：Current pharmaceutical design

authors： Takahashi H,Sano H,Chiba H,Kuroki Y

更新日期：2006-01-01 00:00:00

abstract：:1, 2-Distearoyl-sn-glycero-3-phosphoethanolamine-Poly(ethylene glycol) (DSPE- PEG) is a widely used phospholipids-polymer conjugate in drug delivery applications. It is a biocompatible, biodegradable and amphiphilic material which can also be functionalized with various biomolecules for specific functions. With the em...

journal_title：Current pharmaceutical design

authors： Che J,Okeke CI,Hu ZB,Xu J

更新日期：2015-01-01 00:00:00

abstract：:The formation of liposomes, nanoparticle micelles, and related systems by mixtures of drugs and/or surfactants is of major relevance for the design of drug delivery systems. We can design new systems using different compounds. Traditionally these systems are created by trial and error using experimental data. However,...

journal_title：Current pharmaceutical design

authors： Messina PV,Besada-Porto JM,Rial R,González-Díaz H,Ruso JM

更新日期：2016-01-01 00:00:00

abstract：:This review will focus on the construction, refinement, and validation of G Protein-coupled receptor models for the purpose of structure-based virtual screening. Practical tips and tricks derived from concrete modeling and virtual screening exercises to overcome the problems and pitfalls associated with the different ...

journal_title：Current pharmaceutical design

authors： de Graaf C,Rognan D

更新日期：2009-01-01 00:00:00

abstract：:Mesenchymal stem cells (MSCs) were first isolated more than 50 years ago from the bone marrow. Currently MSCs may also be isolated from several alternative sources and they have been used in more than a hundred clinical trials worldwide to treat a wide variety of diseases. The MSCs mechanism of action is undefined and...

journal_title：Current pharmaceutical design

authors： de Girolamo L,Lucarelli E,Alessandri G,Avanzini MA,Bernardo ME,Biagi E,Brini AT,D'Amico G,Fagioli F,Ferrero I,Locatelli F,Maccario R,Marazzi M,Parolini O,Pessina A,Torre ML,Italian Mesenchymal Stem Cell Group

更新日期：2013-01-01 00:00:00

abstract：:Various growth factors such as the platelet derived growth factor (PDGF), insulin-like growth factor (IGF), epidermal growth factor (EGF), fibroblast growth factor (FGF), and vascular endothelial growth factor (VEGF) transduce their mitogenic signals through the activation of tyrosine kinase receptors (RTKs). Since en...

journal_title：Current pharmaceutical design

authors： Gouni-Berthold I,Sachinidis A

更新日期：2004-01-01 00:00:00

abstract：:The acidic amino acid L-glutamate acts as both a primary excitatory neurotransmitter and a potential neurotoxin within the mammalian central nervous system. Functionally juxtaposed between these neurophysiological and pathological actions are an assorted group of integral membrane transporter proteins that rapidly and...

journal_title：Current pharmaceutical design

authors： Bridges RJ,Kavanaugh MP,Chamberlin AR

更新日期：1999-05-01 00:00:00

abstract：:Inflammatory bowel disease (IBD) is a group of disorders characterized by chronic inflammation within the gastrointestinal tract. It is a multifactorial disease associated with immune-cell mediated oxidative damage to the intestinal mucosa. There is no cure for IBD, but anti-cytokine therapy can limit target inflammat...

journal_title：Current pharmaceutical design

authors： Dostie KE,Thees AV,Lynes MA

更新日期：2018-01-01 00:00:00